Fast Company | Ranked Top 3, Insilico Medicine included in Fast Company's Most Innovative Companies list

Under the umbrella of Fast Company, a globally authoritative business media outlet,The 2026 'World's Most Innovative Companies' listwas recently released, focusing on innovative momentum and covering 59 subfields. It honors outstanding companies that explore boundaries, shape industry landscapes, and foster cultural consensus,Insilico Medicine (03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI)and selected companies include those whichranked third among the most innovative companies in the biotech sector.Notable awardees this year includeGoogle, NVIDIA, Adidas, Walmartand other well-known enterprises.

It is worth mentioning that Insilico Medicine was previously included in Fast Company's'Most Innovative' company list in 2024., this renewed selection is based on Insilico Medicine'sdemonstrated clinical translation capabilities in generative AI-driven drug discovery, as well as itssignificant progress in commercialization and capital markets, marking the recognition of the company's industry-leading innovative contributions.

In 2025, Insilico Medicine's leading pipeline Rentosertib (ISM001-055) announcedPhase IIa clinical trial data. As the world’s first small molecule drug fully discovered and designed by AI, Rentosertib showed a trend of improving lung function efficacy in patients with idiopathic pulmonary fibrosis (IPF) and demonstrated good safety. Additionally, Insilico Medicine continues to deepen its innovation in AI-driven drug discovery, with multiple self-developed pipelines advancing into preclinical or clinical validation stages.

In terms of commercial collaborations, Insilico Medicine has steadily expanded its multidimensional partnerships with global pharmaceutical companies, technological pioneers, and research institutions, covering therapeutic areas in urgent need of innovative solutions such as cardiometabolic diseases, central nervous system (CNS) disorders, and women's reproductive health. On December 30, 2025, Insilico Medicine successfully listed on the Hong Kong Stock Exchange, completingthe largest Biotech IPO in Hong Kong for the year, indicating a strong development outlook.

Alex Zhavoronkov, founder and CEO of Insilico Medicine, stated, "We are honored to be recognized on Fast Company's list of the world's most innovative companies, which demonstrates the strength of our end-to-end AI platform and our ability to continuously translate AI achievements into clinical-stage pipelines. We believe that generative AI is fundamentally reshaping the logic of drug innovation and design, and we are witnessing the beginning of a new era."

As a pioneer in applying generative artificial intelligence to drug discovery, Insilico Medicine continues to drive the deep integration of cutting-edge AI technologies with extensive scientific expertise, building a diversified internal pipeline covering more than 40 innovative projects, 28 of which have reached the IND-enabling stage, with 12 obtaining clinical trial approvals.

In addition to small molecule drug innovations, Insilico Medicine is expanding the diverse applications of generative AI. With the biologics engineering engine Generative Biologics under its Pharma.AI platform, the company continues to empower the development of new molecular entities (New Modalities) such as peptides, nanobodies, antibody-drug conjugates (ADCs), and proteolysis-targeting chimeras (PROTACs). Additionally, Insilico Medicine recently launched MMAI Gym, a specialized model training environment targeting high-barrier fields like biology and chemistry, aiming to provide large language models (LLMs) with professional reasoning capabilities and domain-specific execution across various task types.

The 'World's Most Innovative Companies' list is one of Fast Company’s most renowned and closely watched awards.After extensive evaluation, key players driving change in various subfields stand out from thousands of award applications, forming an innovation map that spans the globe and multiple industries. The selected companies include both early-stage startups and the world’s most valuable leading enterprises.

Fast Company Editor-in-Chief Brendan Vaughan stated,The 'Most Innovative Companies' list aims to recognize organizations that not only adapt to change but also lead it. This year’s winning companies combine bold ideas with measurable real-world impact, turning breakthrough innovations into tangible value, symbolizing the future landscape of their industries by 2026. In their respective sectors, these winners are setting benchmarks for growth and providing replicable paradigms for continuous innovation.

About Insilico Medicine

Insilico Medicine is a global pioneer biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery and drive innovation in the life sciences sector, enabling longer and healthier lives for humanity. On December 30, 2025, the company was listed on the Main Board of the Hong Kong Stock Exchange, with stock code: 03696.HK.

Using its self-developed Pharma.AI platform and advanced automated biology laboratories, Insilico Medicine is providing innovative drug solutions for unmet disease areas such as fibrosis, oncology, immunology, pain, obesity, and metabolic disorders. Additionally, Insilico Medicine continues to expand the application of Pharma.AI into diversified fields such as advanced materials, agriculture, nutritional products, and veterinary drugs. For more information, please visit www.insilico.com.

20K Views